Apogee Therapeutics

APOGEE THERAPEUTICS INC

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMBO

APGE

ATON

BAOS

DGNX

GLDG

GTBP

PLUG

RELL

TCRT

TELO

TTRX

VNTG

WOLF

XBIO

Connexa Sports Technologies Inc. - Common Stock

YYAI

ZCMD

RELL sorprendió al mercado con ganancias y ventas superiores a las previstas, impulsando sus acciones más del 20 % en el premercado.

Acciones de Richardson Electronics (RELL) suben un 20%; Aquí están 20 acciones que se mueven en el premarket

Apogee Therapeutics Inc

Earnings

Press Releases

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

Health Care

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

IPOs

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

Financing

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alkermes

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Immunovant

Krystal Biotech

Kymera Therapeutics

Jyong Biotech

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

uniQure

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Zai Lab

BTIG

RBC Capital

B of A Securities

Guggenheim

Citigroup

Comments

Apogee Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL